Rapport Therapeutics, Inc. Common Stock
Status: Publicly traded
Direct answer
Rapport Therapeutics, Inc. Common Stock is publicly traded on NASDAQ under the ticker RAPP.
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar...
Can you invest in Rapport Therapeutics, Inc. Common Stock?
Yes. Rapport Therapeutics, Inc. Common Stock is publicly traded on NASDAQ under the ticker RAPP.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Rapport Therapeutics, Inc. Common Stock
Detailed equity research is provided by MarketSnap.